Browse CD207

Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type II membrane protein Note=Found in Birbeck granules (BGs), which are organelles consisting of superimposed and zippered membranes.
Domain PF00059 Lectin C-type domain
Function

Calcium-dependent lectin displaying mannose-binding specificity. Induces the formation of Birbeck granules (BGs); is a potent regulator of membrane superimposition and zippering. Binds to sulfated as well as mannosylated glycans, keratan sulfate (KS) and beta-glucans. Facilitates uptake of antigens and is involved in the routing and/or processing of antigen for presentation to T cells. Major receptor on primary Langerhans cells for Candida species, Saccharomyces species, and Malassezia furfur. Protects against human immunodeficiency virus-1 (HIV-1) infection. Binds to high-mannose structures present on the envelope glycoprotein which is followed by subsequent targeting of the virus to the Birbeck granules leading to its rapid degradation.

> Gene Ontology
 
Biological Process GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent
GO:0006898 receptor-mediated endocytosis
GO:0009615 response to virus
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I
GO:0048002 antigen processing and presentation of peptide antigen
GO:0051607 defense response to virus
GO:0098542 defense response to other organism
Molecular Function GO:0005537 mannose binding
GO:0030246 carbohydrate binding
GO:0048029 monosaccharide binding
Cellular Component GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030669 clathrin-coated endocytic vesicle membrane
GO:0031901 early endosome membrane
GO:0044440 endosomal part
GO:0045334 clathrin-coated endocytic vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1236978: Cross-presentation of soluble exogenous antigens (endosomes)
R-HSA-168256: Immune System
Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD207 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD207 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD207 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4540.311
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1230.871
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8770.166
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.410.527
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6730.48
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0550.967
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.2770.0587
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2610.195
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.5420.163
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2210.713
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0080.992
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6490.0135
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD207 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD207. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD207. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD207.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD207. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD207 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD207 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD207
NameCD207 molecule, langerin
Aliases Langerin; CLEC4K; CD207 antigen, langerin; C-type lectin domain family 4, member K; Langerhans cell specific ......
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD207 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.